Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary financial results for the three months and twelve months ended December 31, 2020.
Fourth Quarter 2020 Preliminary Financial Results Summary:
Fiscal Year 2020 Preliminary Financial Results Summary:
About Organogenesis Holdings Inc.
Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com 443-213-0500 Press and Media Inquiries: Organogenesis Lori Freedman email@example.com
IoT Transportation Solutions for Government Agencies
IoT Evolution #TECHSUPERSHOW Expo Hall Open